Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeNZB vaccine 3-dose versus 4-dose schedule in healthy university students
2005-003570-22Phase 2Completed
- Sponsor
- Health Protection Agency
- Start
- Aug 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NZ MenB OMV vaccine in meningococcal disease (2 arms), sponsored by Health Protection Agency. Primary endpoint: Primary immunogenicity endpoint. Started Aug 2005; status: completed.
02
Drugs
NZ MenB OMV vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2005-003570-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003570-22.